Literature DB >> 6601013

Splenic B cells function as immunogenic antigen-presenting cells for the induction of effector T cells.

E Tzehoval, P De Baetselier, Y Ron, B Tartakovsky, M Feldman, S Segal.   

Abstract

Previous studies performed in our laboratory have revealed that an ordered, sequential, tricellular interaction is obligatory for the antigen-driven induction of a specific effector memory T cell. Thus, it was found that antigen-pulsed peritoneal macrophages signal, in spleen cells, the generation of antigen-specific initiator lymphocytes. These lymphocytes, following injection to syngeneic recipients, recruit, in the draining lymph nodes, "virgin" antigen-reactive T lymphocytes. Although the nature of the first and last cell in the interacting sequence was well characterized, the identity of the intermediary initiator splenic cell was obscure. Studies were carried out to characterize the nature of the splenic initiator cells. It was found that spleen cells from nu/nu, adult thymectomized and neonatal thymectomized, or spleen cells from normal donors which had been subjected to cytolysis using anti-Thy-1.2 antibodies in the presence of complement, did generate, following interaction with keyhole limpet hemocyanin (KLH)-fed macrophages, specific initiator cells. Carrageenan impairment of spleen macrophages did not affect the generation of initiator cells, nor did the depletion of dendritic cells from the spleen. On the other hand highly enriched B cell, but not highly enriched T cell populations, when seeded on KLH-pulsed macrophages, generated antigen-specific initiators, which, in vivo, recruited antigen-reactive T cells. It thus appeared that B lymphocytes can function as intermediary obligatory antigen-presenting cells and actively transfer immunogenic signals from peritoneal antigen-presenting cells to T lymphocytes. These findings may therefore suggest that antigen-specific B cells do not function solely as antibody-producing cells, but, once activated by macrophages, may control the induction and differentiation of some antigen-reactive T cell subsets. Thus, one can view the B cell as an important regulatory cell of both cellular and humoral immune functions. The significance of this observation with regard to Ir gene control at the level of B lymphocytes is discussed.

Entities:  

Mesh:

Year:  1983        PMID: 6601013     DOI: 10.1002/eji.1830130202

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  B cells modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the acute phase of Trypanosoma cruzi infection.

Authors:  Fabiola Cardillo; Edilberto Postol; Jorge Nihei; Luiz S Aroeira; Auro Nomizo; José Mengel
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

2.  The role of antibodies in the regulation of delayed-type hypersensitivity.

Authors:  Y Morikawa; K Kuribayashi; F Yoshikawa; K Fujita; A Mizushima; K Kakudo
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

3.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

4.  Inhibition of antigen trafficking through scavenger receptor A.

Authors:  Maurice T Raycroft; Bohdan P Harvey; Matthew J Bruck; Mark J Mamula
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

5.  Tamoxifen Suppresses the Immune Response to Plasmodium berghei ANKA and Exacerbates Symptomatology.

Authors:  Luis Antonio Cervantes-Candelas; Jesús Aguilar-Castro; Fidel Orlando Buendía-González; Omar Fernández-Rivera; Armando Cervantes-Sandoval; Jorge Morales-Montor; Martha Legorreta-Herrera
Journal:  Pathogens       Date:  2021-06-12

6.  T cell development in B cell-deficient mice. II. Serological characterization of suppressor T cell factors (TsF1) produced in normal mice and in mice treated chronically with rabbit anti-mouse IgM antibodies.

Authors:  M S Sy; K T Hayglass; B Benacerraf
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.